NewsBytes
    Hindi
    More
    In the news
    Mukesh Ambani
    WhatsApp
    Reliance Jio
    OPPO
    Vivo
    Sensex
    Bitcoin
    NewsBytes
    Hindi
    NewsBytes
    User Placeholder

    Hi,

    Logout


    India Business World Politics Sports Technology Entertainment Auto Lifestyle Inspirational Career Bengaluru Delhi Mumbai Visual Stories Find Cricket Statistics Phones Reviews Fitness Bands Reviews Speakers Reviews

    Download Android App

    Follow us on
    • Facebook
    • Twitter
    • Linkedin
     
    Home / News / Business News / Female-libido enhancer Addyi's maker sold for $1 billion
    Business

    Female-libido enhancer Addyi's maker sold for $1 billion

    Female-libido enhancer Addyi's maker sold for $1 billion
    Written by Vaneet Randhawa
    Aug 21, 2015, 07:26 pm 3 min read
    Female-libido enhancer Addyi's maker sold for $1 billion

    The Wall Street Journal reported that Valeant Pharmaceuticals International, Inc will buy Raleigh-based Sprout Pharmaceuticals for approximately $1 billion. Interestingly, this acquisition comes before the expected sale of female libido enhancer Addyi from 17 October 2015, which had been created by Sprout Pharmaceuticals. Valeant is planning to keep Sprout's leadership team unchanged and maintain its offices in Raleigh.

    Valeant's push-start to become biggest pharma company

    ICN Pharmaceuticals which later became Valeant was formed as a US business by merging of several group units in the 1990s. In 2010, Valeant was born out of a merger of its U.S. predecessor and Canada's Biovail Corp. Valeant has a portfolio of more than 500 products to its name. Since its inception, Valeant has stuck to making multi-billion dollar deals aimed at expansion.

    World famous Wellbutrin antidepressant- a Valeant product

    Valeant's most famous drug is Wellbutrin, an anti-depressant and Kinerase which uses Kinetin as an ingredient and reduces freckles and spots on the skin.

    Bausch & Lomb acquired by Valeant

    Valeant Pharmaceuticals International Inc. acquired Warburg Pincus LLC's eye-care company Bausch & Lomb Holdings Inc for $8.7 billion. Of the $8.7 billion, $4.2 billion would be used to pay Bausch & Lomb's debts. This deal is Valeant's biggest deal since its creation in 2010. With this deal, Valeant will compete in the fast growing, and highly specialized ophthalmology market.

    Allergan slips out of Valeant's fingers

    Valeant Pharmaceuticals' $47 billion bid to take over U.S. drugmaker Allergan, mostly known as the creator of Botox failed to follow through. Valeant's business model to cut costs was not considered sustainable by Allergen who claimed that the offer was too risky. This came after Valeant's April 22 declaration saying it expected Allergan to make at least $2.7 billion in annual cost cuts.

    Allergan's CEO explains why Valiant deal failed

    "Valeant's model of cutting and slashing really doesn't work for more than a very short period of time," Allergan Chief Executive Officer David Pyott said.

    On to the stomach-disorders treatment market

    Valeant Pharmaceuticals International Inc. divulged its plans to buy Salix Pharmaceuticals Ltd. in a $10 billion deal. The deal will make Valeant a household name for treatment of stomach disorders like traveller's diarrhoea. Valeant's deal hoped to tap the U.S. market for stomach-disorder treatments which is valued at $5 billion and is expected to grow by 5% annually.

    Valiant becomes Canada's largest company

    In July 2015, Valeant Pharmaceuticals International Inc. eclipsed the Royal Bank of Canada to become Canada's largest company by market value. Valeant shares rose more than 9% to $341.02 per share (its 52 week high) and the company reached a market value of $116.3 billion on the Toronto Stock Exchange. The pharmaceutical giant has surged 105% in the current year.

    What is Addyi?

    Addyi or what is popularly being termed as a 'female Viagra' is Sprout's latest creation, which has managed to get approval from the Food and Drugs Administration, USA but with 'severe warning'.

    Share this timeline
    Facebook
    Whatsapp
    Twitter
    Linkedin
    Latest

    Latest

    'Grave concern': Rijiju on SC publishing IB, R&AW classified reports Kiren Rijiju
    India rout NZ, claim top spot in ICC ODI Rankings India vs New Zealand Cricket
    New Zealand opener Devon Conway scores his third ODI century Devon Conway
    IND vs NZ: Hardik Pandya registers his ninth ODI half-century Hardik Pandya

    Love Business News?

    Subscribe to stay updated.

    Business Thumbnail
    Indian Premier League (IPL) Celebrity Hollywood Bollywood UEFA Champions League Tennis Football Smartphones Cryptocurrency Upcoming Movies Premier League Cricket News Latest automobiles Latest Cars Upcoming Cars Latest Bikes Upcoming Tablets
    About Us Privacy Policy Terms & Conditions Contact Us Ethical Conduct Grievance Redressal News News Archive Topics Archive Download DevBytes Find Cricket Statistics
    Follow us on
    Facebook Twitter Linkedin
    All rights reserved © NewsBytes 2023